Testing of davunetide for intranasal administration in a pre-clinical model over-expressing alpha synuclein
Allon Therapeutics Inc.
Previously, in a study sponsored by MJFF, the investigators found that treatment with davunetide for two months resulted in an impact on brain pathology as evidenced by a reduction in alpha-synuclein aggregates and a modest improvement in the pre-clinical model’s motor behavior. The current project will expand on these preliminary findings to assess if different doses and/or longer treatment duration will result in a more robust impact on brain pathology and/or improvement in motor function. The alpha-synuclein pre-clinical model was chosen because it progressively develops both the motor function problems and the neuropathology seen in PD.